Heather J. Landau, MD | oneAMYLOIDOSISvoice
×
Or register here
Global Search

Trusted Resources: People & Places

Healthcare providers, researchers, and advocates

Back to People / Healthcare Professionals
Heather J. Landau, MD

Heather J. Landau, MD

Healthcare Professional
Oncologist - Hematologist
Memorial Sloan Kettering Cancer Center
1275 York Avenue
New York, New York, United States
Heather J. Landau is a board-certified oncologist and hematologist, and works as part of a multidisciplinary team caring for patients with hematologic disorders. She received her medical degree from Upstate Medical University followed by residency in internal medicine from University of Colorado Health Sciences Center and fellowship in hematology/oncology from Memorial Sloan Kettering Cancer Center.
 
Dr. Landau has a special interest and expertise in treating patients with disorders that arise in white blood cells called plasma cells, including multiple myeloma and light chain (AL) amyloidosis. Her research focuses on new treatment approaches for plasma cell disorders. Along with her colleagues she is testing targeted therapies, immunomodulatory agents, and stem cell transplantation to arrive at more-effective and less-toxic regimens for these diseases.
 
She is co-leading a study comparing the effectiveness of an immunomodulatory agent (lenalidomide) with that of high-dose therapy and stem cell transplantation. She is also leading a trial to determine the most effective post-stem cell transplant therapy. As the principal investigator of an ongoing trial using a risk-adapted approach to stem cell transplant followed by novel agents in AL amyloidosis, she has had the opportunity to present exciting results demonstrating significant activity and low toxicity with this approach.
 
 
Representative Publications:
 
 
 
 
 
 
view profile

Related Content

To improve your experience on this site, we use cookies. This includes cookies essential for the basic functioning of our website, cookies for analytics purposes, and cookies enabling us to personalize site content. By clicking on 'Accept' or any content on this site, you agree that cookies can be placed. You may adjust your browser's cookie settings to suit your preferences.
More information

The cookie settings on this website are set to "allow cookies" to give you the best browsing experience possible. If you continue to use this website without changing your cookie settings or you click "Accept" below then you are consenting to this.

Close

Community Key Collaborator

Support for this landing page is provided by an independent education grant from

Translation of this platform made possible through an independent education grant from

© 2024 rareLife solutions Inc.

To improve your experience on this site, we use cookies. This includes cookies essential for the basic functioning of our website, cookies for analytics purposes, and cookies enabling us to personalize site content. By clicking on 'Accept' or any content on this site, you agree that cookies can be placed. You may adjust your browser's cookie settings to suit your preferences.
More information

The cookie settings on this website are set to "allow cookies" to give you the best browsing experience possible. If you continue to use this website without changing your cookie settings or you click "Accept" below then you are consenting to this.

Close